Myotonic Dystrophy Drug Development Pipeline - Dec. 2024

Authority Sections Authority Companied Online Onl	COMPANY	PROGRAM/ LEAD CANDIDATE	MODALITY	DM SUBTYPE	PRE- CLINICAL PHASE 1	PHASE 2 PHASE 3	DRUG TARGET/ MECHANISM	PRESS RELEASES & MORE	MDF CONFERENCE INDUSTRY UPDATE	MDF MEET-THE-DM- DRUG-DEVELOPERS
Compared Control Compared Control Compared Control	AMO Pharma Ltd	Tideglusib	Small Molecule	CDM / DM1	P H A R M A			AMO Pharma News	2024 Industry Update	2023 Webinar
	Avidity Biosciences			DM1	AVIDITY BIOSCIENCES		DMPK	<u>Avidity News</u>	2024 Industry Update	2024 Webinar
Part	Lupin Neurosciences	Mexiletine	Small Molecule	DM1 / DM2	LUPIN NEUROSCIENCES		Sodium Channels	<u>Lupin News</u>		2024 Webinar
ATX ATX ATX ATX Attenues inclinate Old Part Old Part Old	Harmony Biosciences	Pitolisant	Small Molecule	DM1	H3 HARMONY BIOSCIENCES			Harmony News	2023 Industry Update	2022 Webinar
Section 1 ALL III Disposed Consideration 1001 1001 1000 1000 1000 1000 1000 10	Dyne Therapeutics	Dyne 101		DM1	YDyne THERAPEUTICS		DMPK	<u>Dyne News</u>	2024 Industry Update	2024 Webinar
Description of the Potential Control of the Po	ARTHEx Biotech	ATX-01		DM1 / DM2	ARTHEX			ARTHEx News	2024 Industry Update	2024 Webinar
Note and Committee of the Committee of t	<u>Vertex</u>	VX-670		DM1	VERTEX		DMPK	<u>Vertex News</u>		
Comparison Teconomics Comp	<u>PepGen</u>	PGN-EDODM1		DM1	PepGen [™]		DMPK	PepGen News	2024 Industry Update	2024 Webinar
Service Theraposition 10V-161 Stem Cell-Secreted Proteins DM1 10V-161 PM5 PM51 Small Melecule DM1 10V-161 PM51 PM51 Small Melecule DM1 10V-161 PM51 PM51	Arrowhead Pharmaceuticals	ARO-DM1	_	DM1	of arrowhead pharmacouricals		r(CUG) of DMPK	Arrowhead News		
Reports Thereportes PMS1 Small Molecule DM1 Reports DMPK Send Mercy Advance Associated Visus Advance Associated Visus Advance Associated Visus DMPK Acre is Nones DMPK Eleverine Nones DMPK Design Nones DMPK DMPK DMPK DMPK DMPK DMPK DMPK DMPK	Expansion Therapeutics	DM1 (CUG)	Small Molecule	DM1	EXPANS ON THERAPEUTICS		r(CUG) of DMPK	Expansion News	2021 Industry Update	2021 Webinar
Aside Core Therapeur Associated Virsu Anticons Associated Virsu Antico	Juvena Therapeutics	JUV-161	Stem Cell-Secreted Proteins	DM1	Juvena THERAPEUTICS			Juvena News	2024 Industry Update	2024 Webinar
Associated Virus Addeno Associated Virus Addeno Associated Virus DMPK Addeno Associated Virus DMPK Addeno Associated Virus	Rgenta Therapeutics	PMS1	Small Molecule	DM1	Rgenta		r(CUG) of DMPK	Rgenta News	2023 Industry Update	
Actificial Steen Interspection	<u>Sanofi</u>				sanofi		DMPK	Sanofi News	2023 Industry Update	
Linitrope interspectives	Astellas Gene Therapies	AT466		DM1	** astellas GENETHERAPIES		DMPK	<u>Astellas News</u>		
Endonucleases (ASREs) Modalis Therapeutics MDL-202 AAV modalis CRISPR base DMN MODALIS Design Therapeutics Biomolecular Condensates DM1 Despoint Therapeutics RNA-targeted Small Molecule (rSM) DM1 DM1 DM1 DMPK DMPK Design News DMPK Design News DMN Editions DMN DMN DMN DMN DMN DMN DMN DM	GrittGene Therapeutics			DM2	GRITTGENE THERAPEUTICS				2022 Industry Update	
Design Therapeutics Gene Targeting Chimera Small Molecule DM1 Design Therapeutics Biomolecular Condensates DM1 Dewpoint Therapeutics Biomolecular Condensates DM1 DMPK Dewpoint News DMPK DMPK Dewpoint News DMPK Arrakis News DMPK Demail Therapeutics DM1 DMPK Demail Therapeutics DMPK Demail Therapeutics DMPK Demail Therapeutics DMPK Demail Therapeutics DM1 DEMAIL DMPK Demail Therapeutics DM1 DMPK Demail Therapeutics	Enzerna Biosciences			DM1	ENZERNA		r(CUG) of DMPK	Enzerna News		
Small Molecule Devicint Iherapeutics Biomolecular Condensates DM1	Modalis Therapeutics	MDL-202		DM1	MODALIS		DMPK	Modalis News		
Arrakis Therapeutics RNA-targeted Small Molecule (rSM) DM1 Comparison	Design Therapeutics			DM1	DESIGN		r(CUG) of DMPK	<u>Design News</u>		
Kate Therapeutics	Dewpoint Therapeutics		Biomolecular Condensates	DM1	dewpointx		DMPK	Dewpoint News		
Prime Medicine	Arrakis Therapeutics		RNA-targeted Small Molecule (rSM)	DM1	Po arrakis		DMPK	Arrakis News		
Denali Therapeutics DM1 DENALI DMPK Denali News EditForce. Inc. EF-210 Gene Transfer based Delivery of Pentatricopeptide Repeat Protein DM1 Scriptr Global. Inc	Kate Therapeutics			DM1	KATE THERAPEUTICS					
EditForce, Inc. EF-210 Gene Transfer based Delivery of Pentatricopeptide Repeat Protein DM1 Scriptr Global, Inc. DM1 Scriptr	Prime Medicine				prime_ medicine					
Pentatricopeptide Repeat Protein Scriptr Global, Inc. DM1 Scriptr DM1 Scriptr DM1 Scriptr DM1 Scriptr DM1 Scriptr	Denali Therapeutics			DM1	DENALI		DMPK	Denali News		
	EditForce, Inc.	EF-210	_	DM1	EditForce		r(CUG) of DMPK	EditForce News		
Healx Ltd Healx News	Scriptr Global, Inc.			DM1	Scriptr					
	Healx Ltd.			DM1	healx			Healx News		

Note: Academic institutions are not included above. In addition to this list, there are several more companies in the Discovery Phase that have not yet made their DM programs public. Click green arrows above for clinical trial information on Phases 1-3. For locations and details of each clinical trial, visit www.clinicaltrials.gov.

Designed by MDF, this pipeline is in ongoing development and based on publicly available information. Special thanks to **Nate Uhl** for his comprehensive scan of the DM research landscape and original vision for the drug development pipeline. For questions, or to request updates to the pipeline, please contact MDF at info@myotonic.org. To review the Myotonic Dystrophy Research Map visit: www.myotonic-dystrophy-research-map.



